Patient pharmacodynamic biomarker and pk evaluation results from an ongoing phase I dose-escalation study of q702, an axl, mer and csf1r kinase inhibitor in patients with advanced solid tumors

被引：2
|
作者：
Choi, Bae Jung
Devalingam, Devalingam
Alistar, Angela
El-Khoueiry, Anthony
Mita, Alain
Kang, Hwankyu
Choi, Jinho
Ahn, Hyunji
Kim, Jeongjun
Lee, Seung-Joo
Yang, Yeong-In
Ahn, Jiye
Jeon, Borami
Kim, Jaeseung
Nam, Kiyean
机构：
来源：
CANCER RESEARCH | 2023年 / 83卷 / 07期
关键词：
D O I：
10.1158/1538-7445.AM2023-2255
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2255
引用
收藏
页数：3
相关论文
共 50 条
  • [41] A phase I, first-in-human, dose-escalation and dose expansion study of the multitarget kinase inhibitor TT-00420 in patients with advanced solid tumors.
    Piha-Paul, Sarina Anne
    Wan, Qunfang
    Xiong, Wendy
    Peng, Peng
    Yang, Xiaoju
    Wu, Henry
    Ngo, Brenda
    Wu, Frank
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [42] Phase I study of BAY 73-4506, an inhibitor of oncogenic and angiogenic kinases, in patients with advanced solid tumors: Final results of a dose-escalation study
    Frost, A.
    Buechert, M.
    Unger, C.
    Christensen, O.
    Wagner, A.
    Heinig, R. A.
    Scheulen, M. E.
    Strumberg, D.
    Fasol, U.
    Mross, K.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [43] Final results of a phase I dose-escalation study of ON 01910.Na in combination with oxaliplatin in patients with advanced solid tumors
    Ohnuma, T.
    Holland, J. F.
    Goel, S.
    Wilck, E.
    Lehrer, D.
    Ghalib, M. H.
    Chaudhary, I.
    Wilhelm, F.
    Swami, U.
    Mani, S.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [44] TQB2450 in patients with advanced malignant tumors: results from a phase I dose-escalation and expansion study
    Xue, Junli
    Xue, Liqiong
    Tang, Wenbo
    Ge, Xiaoxiao
    Zhao, Wei
    Li, Qun
    Peng, Wei
    Dai, Congqi
    Guo, Ye
    Li, Jin
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2024, 16
  • [45] Phase I dose-escalation and pharmacokinetic (PK) study of sunitinib (SU) plus docetaxel (D) in patients (pts) with advanced solid tumors (STs)
    Traynor, A. M.
    Sandler, A. B.
    Schiller, J. H.
    Ilagan, J.
    Vermeulen, W. L.
    Liu, G.
    Tye, L.
    Verkh, L.
    Chao, R.
    Robert, F.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [46] A Phase I Dose-Escalation Study of LY3405105, a Covalent Inhibitor of Cyclin-Dependent Kinase 7, Administered to Patients With Advanced Solid Tumors
    Garralda, Elena
    Schram, Alison M.
    Bedard, Philippe L.
    Schwartz, Gary K.
    Yuen, Eunice
    McNeely, Samuel C.
    Ribeiro, Silvia
    Cunningham, Jason
    Wang, Yi
    Urunuela, Arantxa
    Xu, Xiaojian
    LoRusso, Patricia
    ONCOLOGIST, 2024, 29 (01): : e131 - e140
  • [47] A phase I dose-escalation and pharmacokinetic (PK) study of sunitinib (SU) plus docetaxel (D) in patients (pts) with advanced solid tumors (STs)
    Robert, F.
    Sandler, A.
    Schiller, J. H.
    Ilagan, J.
    VerMeulen, W.
    Harper, K.
    Liu, G.
    Tye, L.
    Chao, R.
    Traynor, A.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [48] A phase I dose-escalation study of INCB028060, an inhibitor of c-MET receptor tyrosine kinase, in patients with advanced solid tumors.
    Donehower, R. C.
    Scardina, A.
    Hill, M.
    Bowman, J.
    Newton, R. C.
    Liu, X.
    Scherle, P.
    Wang, Q.
    Diamond, S.
    Boer, J.
    Lee, F.
    Gau, T.
    Burris, H. A.
    Bendell, J. C.
    Jones, S. F.
    Infante, J. R.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [49] A phase 1 dose escalation study of BI 831266, an inhibitor of Aurora kinase B, in patients with advanced solid tumors
    Dittrich, Christian
    Fridrik, Michael A.
    Koenigsberg, Robert
    Lee, Chooi
    Goeldner, Rainer-Georg
    Hilbert, James
    Greil, Richard
    INVESTIGATIONAL NEW DRUGS, 2015, 33 (02) : 409 - 422
  • [50] A phase 1 dose escalation study of BI 831266, an inhibitor of Aurora kinase B, in patients with advanced solid tumors
    Christian Dittrich
    Michael A. Fridrik
    Robert Koenigsberg
    Chooi Lee
    Rainer-Georg Goeldner
    James Hilbert
    Richard Greil
    Investigational New Drugs, 2015, 33 : 409 - 422
12345